Presenter: Austin Perlmutter, MD
Original Date: July 21 2024

Brain-related diseases and disorders are among the most debilitating and deadly conditions on Earth. Yet by and large, conventional pharmaceutical management targeting individual neurotransmitters or proteins (e.g., serotonin in depression, amyloid beta in Alzheimer’s dementia) have fallen short of expectations. This has led to a growing interest in identifying additional disease-related pathways and interventions to help ameliorate physical, emotional and economic costs. In this conversation, neuroinflammation and psychedelics have each emerged as areas of intense academic research and potential sources of solutions. Neuroinflammation is now believed to underlie or significantly contribute to mental health, cognitive, neurodevelopmental and behavior disorders and diseases. Psychedelics represent promising compounds for ameliorating a host of brain-related conditions. In this presentation, we’ll explore the known overlap between the two domains while looking ahead towards the promise this may hold for the future of brain health.

NUNM is accredited by the North American Naturopathic Continuing Education Council (NANCEAC). This activity qualifies for 1.0 General, 0.5 Pharmacology CEUs.